Don't quote me on this because I was half-listening, and it was...

Don't quote me on this because I was half-listening, and it was long ago.

From memory, during the Q&A at the AGM they said that it wasn't standard practice to comment on individual generic drug sales. They basically referred back to the Annual Report information: "Testosterone Topical Solution USP, 30mg per actuation was launched through our partner Dash Pharmaceuticals. For the 12 months to December 2021 IQVIA reports an addressable market of US$15 million per year for this product and there are 5 marketed generics;"

So, it's being sold. It's not huge.